With Boehringer In­gel­heim’s help, Roivant churns out an­oth­er Vant to go up against En­deav­or, Im­pact founders

Roivant Sci­ences has added an­oth­er branch to its fam­i­ly tree, un­veil­ing Co­v­ant Ther­a­peu­tics with a $10 mil­lion up­front com­mit­ment from Boehringer In­gel­heim to turn up the heat in can­cer.

The Boston-based drug dis­cov­ery start­up will joint­ly cre­ate a new small mol­e­cule im­munother­a­py with the pri­vate Ger­man phar­ma gi­ant. The deal, made pub­lic Tues­day morn­ing, in­cludes up to $471 mil­lion in fu­ture pay­ments and tiered roy­al­ties, should the prod­uct make it to mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER